Percutaneous cryoablation of hepatic tumors: long-term experience of a large U.S. series
- Peter J. LittrupAffiliated withRhode Island Medical Imaging, Rhode Island Hospital, Brown University Email author
- , Hussein D. AounAffiliated withKarmanos Cancer Institute
- , Barbara AdamAffiliated withKarmanos Cancer Institute
- , Mark KryciaAffiliated withWayne State University School of Medicine
- , Matt PrusAffiliated withKarmanos Cancer Institute
- , Anthony ShieldsAffiliated withKarmanos Cancer Institute
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
To report our long-term experience with percutaneous cryotherapy for primary and metastatic liver tumors, including historical perspectives on complications over time and local recurrence rates.
Materials and methods
Following IRB approval under HIPAA compliance, 342 CT fluoroscopic-guided, percutaneous cryotherapy procedures were performed for 443 masses in 212 outpatients with hepatocellular carcinoma (HCC; N = 36), or metastatic disease (N = 176), grouped as colorectal carcinoma (CRC) and non-CRC metastases. Tumor and ablation sizes were noted in relation to adjacent vasculature. All complications were graded according to standardized criteria. Patients were followed by CT and/or MRI at 1, 3, 6, 12, 18, 24 months and yearly thereafter. Local recurrences were defined as either “procedural” within the ice ablation zone, or “satellite” within 1 cm of the ablation rim to evaluate recurrence patterns.
Average tumor diameter of 2.8 cm was treated by average cryoprobe number of 4.5, which produced CT-visible ice ablation zone diameters averaging 5.2 cm. Grade >3 complications were primarily hematologic [N = 20/342; (5.8%)], and appeared related to pre-procedural anemia/thrombocytopenia, carcinoid tumor type, and large ablation volumes. No significant central biliary leak, strictures, or bilomas were noted. At a mean follow-up of 1.8 years, local tumor recurrences were 5.5%, 11.1%, and 9.4% for HCC, CRC, and non-CRC metastases, respectively, consisting mainly of satellite foci. No significant difference was noted for local recurrences near major blood vessels or tumors >3 cm diameter.
Percutaneous hepatic cryotherapy is a well-visualized, safe procedure that produces very low local recurrence rates, even for tumors near vasculature and diameters over 3 cm. Cryoablation deserves to be in the armamentarium of percutaneous hepatic ablation, especially with careful patient selection for tumors <4 cm and patients with platelet counts >100,000. Percutaneous hepatic cryoablation represents a highly flexible technique with particular benefits near central biliary structures and/or adjacent crucial structures.
KeywordsCryoablation Liver tumors Hepatocellular carcinoma Metastases Recurrence Complication
- Percutaneous cryoablation of hepatic tumors: long-term experience of a large U.S. series
Volume 41, Issue 4 , pp 767-780
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Liver tumors
- Hepatocellular carcinoma
- Industry Sectors
- Author Affiliations
- 1. Rhode Island Medical Imaging, Rhode Island Hospital, Brown University, Providence, RI, USA
- 2. Karmanos Cancer Institute, 110 East Warren, Hudson-Weber Building, Suite 504, Detroit, MI, 48201, USA
- 3. Wayne State University School of Medicine, Detroit, MI, USA